Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "Vaccine Contract Manufacturing Market Report 2026-2036" report has been added to ResearchAndMarkets.com's offering.
Overall world revenue for the Vaccine Contract Manufacturing Market: In terms of value the market will surpass US$3.90 billion in 2026, the work calculates. The publisher predicts strong revenue growth through to 2036. The work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Outsourcing as a Core Structural Model in Vaccine Contract Manufacturing
Vaccine manufacturing is increasingly being treated as a strategic capability that does not necessarily need to be owned and operated in-house. Developers are re-evaluating the long-term economics of maintaining specialised vaccine production facilities, particularly as regulatory requirements, technological complexity and compliance costs continue to intensify across major markets.
As a result, contract manufacturing organisations are being integrated earlier into development programmes and retained for longer commercial partnerships, spanning late-stage clinical production through to full-scale commercial supply. This reflects a deliberate shift towards operational agility, enabling vaccine sponsors to scale capacity, rebalance portfolios and respond rapidly to public-health demand without committing significant capital to fixed infrastructure.
Consequently, the structural growth of outsourcing in the vaccine sector is being underpinned by capital efficiency considerations, reduced balance-sheet risk and the strategic imperative to shorten development and commercialisation timelines.
What would be the Impact of US Trade Tariffs on the Global Vaccine Contract Manufacturing Market?
US trade tariffs are likely to generate sustained cost pressures and prompt selective operational recalibration across the global vaccine contract manufacturing market, rather than a uniform industry-wide disruption. Tariffs on imported bioprocessing equipment, single-use consumables, process intermediates and certain specialised raw materials would increase manufacturing input costs, particularly for contract manufacturing organisations (CMOs) that rely on globally integrated supply chains, imported single-use technologies, and cross-border procurement of critical inputs such as filters, resins and sterile packaging components. In the near term, this is expected to affect pricing negotiations, programme timelines and margin visibility for both vaccine sponsors and manufacturing partners, with smaller CMOs and development-stage projects likely to experience greater cost pass-through than large-scale commercial programmes.
Over the medium to long term, tariff-related uncertainty is likely to accelerate structural shifts towards regional manufacturing localisation and supply-chain diversification, but the extent of relocation will vary by technology platform. Traditional protein-based and viral-vector manufacturing may see more regionalisation, whereas highly specialised platforms such as mRNA are likely to remain concentrated in a smaller number of advanced facilities due to technical complexity and capital intensity. Vaccine developers are expected to prioritise CMOs with domestic or tariff-shielded production footprints, stable access to critical single-use suppliers, and proven regulatory track records with the US Food and Drug Administration. In response, CMOs are likely to expand regional capacity, implement dual-sourcing strategies for key consumables, and invest in localised fill-finish infrastructure to reduce exposure to border frictions.
US-based manufacturers may benefit from reshoring incentives, public-private preparedness programmes and priority government procurement commitments, which could partially offset tariff-driven cost increases. By contrast, non-US CMOs are expected to pursue targeted US investments, joint ventures, or strategic partnerships with domestic players to maintain market access, rather than fully relocating production. Overall, tariffs are more likely to reshape supply-chain architecture and investment patterns in vaccine contract manufacturing than to materially constrain global supply in the short term.
Key Questions Answered
- How is the vaccine contract manufacturing market evolving?
- What is driving and restraining the vaccine contract manufacturing market?
- How will each vaccine contract manufacturing submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2036?
- How will the market shares for each vaccine contract manufacturing submarket develop from 2026 to 2036?
- What will be the main driver for the overall market from 2026 to 2036?
- Will leading vaccine contract manufacturing markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2036 and which geographical region will lead the market in 2036?
- Who are the leading players and what are their prospects over the forecast period?
- What are the vaccine contract manufacturing projects for these leading companies?
- How will the industry evolve during the period between 2026 and 2036? What are the implications ofvaccine contract manufacturing projects taking place now and over the next 10 years?
- Is there a greater need for product commercialisation to further scale the vaccine contract manufacturing market?
- Where is the vaccine contract manufacturing market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
Market Dynamics
Market Driving Factors
- Growth in Infectious Diseases
- Stakeholder Cooperation Maximizes Manufacturing Capacity
- Advancements in Single-use and Modular Facilities
- CDMO Platform Bundling for mRNA and Viral-vector Tech
Market Restraining Factors
- Escalating Biologics Grade Raw Materials Costs
- Regulatory Lag in Tech-Transfer Validation
- Cold Chain Gaps in Emerging Markets
Market Opportunities
- New Vaccine Technologies
- Gene Based Vaccines
Leading Companies
- Ajinomoto Bio-Pharma
- Batavia Biosciences B.V.
- Bavarian Nordic
- Catalent, Inc
- Charles River Laboratories
- Curia Global, Inc.
- Emergent BioSolutions
- FUJIFILM Holdings Corporation
- ICON plc
- IDT Biologika
- Lonza
- Recipharm AB
- Richter-Helm BioLogics GmbH & Co. KG
- WuXi Biologics
Segments Covered in the Report
Type
- Subunit Vaccines
- Live Attenuated Vaccines
- Conjugate Vaccines
- Inactivated Vaccines
- Toxoid Vaccines
- Viral Vector Vaccines
- Recombinant Vector Vaccines
- Other Vaccine Types
Process
- Upstream Process
- Downstream Process
End-use
- Human Use
- Veterinary
Operation
- Preclinical
- Clinical
- Commercial
Company Size
- Small Manufacturers
- Mid-sized Manufacturers
- Large Manufacturers
- Very Large Manufacturers
Full List of Companies Featured
- Ajinomoto Bio-Pharma
- Batavia Biosciences B.V.
- Bavarian Nordic
- Catalent, Inc
- Charles River Laboratories
- Curia Global, Inc.
- Emergent BioSolutions
- FUJIFILM Holdings Corporation
- ICON plc
- IDT Biologika
- Lonza
- Recipharm AB
- Richter-Helm BioLogics GmbH & Co. KG
- WuXi Biologics
- AAVantgarde
- AtkinsRealis
- Batavia Biosciences Limited
- Bharat Biotech International Ltd
- Bilthoven Biologicals B.V.
- Biological E. Limited
- Bionova Scientific
- Bora Pharmaceuticals Co., Ltd.
- CordenPharma
- Delonix Bioworks
- Delpharm
- Emervax
- Ethris
- Galapagos NV
- Jubilant HollisterStier
- Kindeva Drug Delivery
- Meiji Seika Pharma
- PANTHER
- ProductLife Group (PLG)
- Siren Biotechnology
- Terumo Corporation
- Valneva SE
- Virogen Biotechnology Inc.
- VISEN Pharmaceuticals
- Wacker Chemie AG
- Wheeler Bio, Inc.
- Association of the British Pharmaceutical Industry (ABPI)
- Biotechnology Innovation Organization (BIO)
- Coalition for Epidemic Preparedness Innovations (CEPI)
- Developing Countries Vaccine Manufacturers Network (DCVMN)
- European Federation of Pharmaceutical Industries and Associations (EFPIA)
- International Alliance for Biological Standardization (IABS)
- International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)
- International Pharmaceutical Federation (FIP)
- International Society for Vaccines (ISV)
- International Vaccine Institute (IVI)
- Innovative Medicines Canada (IMC)
- Japan Pharmaceutical Manufacturers Association (JPMA)
- Parenteral Drug Association (PDA)
- Pharmaceutical Research and Manufacturers of America (PhRMA)
- World Health Organization (WHO)
For more information about this report visit https://www.researchandmarkets.com/r/1jrlrx
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
